Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
Cervical Cancer, Vaginal Cancer
About this trial
This is an interventional treatment trial for Cervical Cancer focused on measuring recurrent cervical cancer, recurrent vaginal cancer, vaginal clear cell adenocarcinoma, cervical adenocarcinoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed advanced, persistent, or recurrent clear cell adenocarcinoma of the vagina or cervix Documented disease progression after local therapy required Disease must be considered incurable Bidimensionally measurable disease required by physical examination or medical imaging PATIENT CHARACTERISTICS: Age: Any age Performance status: GOG 0-2 Hematopoietic: WBC at least 3,000 AGC at least 1,500 Platelets at least 100,000 Hepatic: Bilirubin no more than 1.5 times normal AST no more than 3 times normal Alkaline phosphatase no more than 3 times normal Renal: Creatinine no more than 2.0 mg/dL Other: Not eligible for a higher priority GOG protocol No significant infection No prior or concomitant second malignancy except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY: At least 3 weeks since therapy directed at malignancy Biologic therapy: Not specified Chemotherapy: No more than 1 prior chemotherapy regimen (either single or combination cytotoxic drug therapy) No prior paclitaxel Recovery from prior chemotherapy required Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy for recurrent disease except a low dose, single fraction used to abrogate menorrhagia Recovery from prior radiotherapy required Surgery: Recovery from prior surgery required
Sites / Locations
- University of Alabama Comprehensive Cancer Center
- USC/Norris Comprehensive Cancer Center
- Jonsson Comprehensive Cancer Center, UCLA
- Women's Cancer Center
- Stanford University Medical Center
- University of Colorado Cancer Center
- Vincent T. Lombardi Cancer Research Center, Georgetown University
- Walter Reed Army Medical Center
- H. Lee Moffitt Cancer Center and Research Institute
- Emory University Hospital - Atlanta
- MBCCOP - Hawaii
- Rush-Presbyterian-St. Luke's Medical Center
- University of Chicago Cancer Research Center
- Indiana University Cancer Center
- University of Iowa Hospitals and Clinics
- Albert B. Chandler Medical Center, University of Kentucky
- Johns Hopkins Oncology Center
- University of Massachusetts Memorial Medical Center
- CCOP - Ann Arbor Regional
- Barbara Ann Karmanos Cancer Institute
- University of Minnesota Cancer Center
- University of Mississippi Medical Center
- Washington University School of Medicine
- Cooper Hospital/University Medical Center
- Cancer Center of Albany Medical Center
- State University of New York Health Science Center at Brooklyn
- Memorial Sloan-Kettering Cancer Center
- University of Rochester Cancer Center
- State University of New York Health Sciences Center - Stony Brook
- Lineberger Comprehensive Cancer Center, UNC
- Duke Comprehensive Cancer Center
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
- Barrett Cancer Center, The University Hospital
- Ireland Cancer Center
- Cleveland Clinic Cancer Center
- Arthur G. James Cancer Hospital - Ohio State University
- University of Oklahoma College of Medicine
- Abington Memorial Hospital
- Milton S. Hershey Medical Center
- University of Pennsylvania Cancer Center
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
- Pennsylvania Hospital
- Fox Chase Cancer Center
- Medical University of South Carolina
- CCOP - Upstate Carolina
- Simmons Cancer Center - Dallas
- University of Texas - MD Anderson Cancer Center
- Cancer Center, University of Virginia HSC
- University of Washington Medical Center
- Tacoma General Hospital